RxDoctor Payments Data

Gil Nieves, MD

Urology · San Juan, PRNPI 1477754000

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Verity Pharmaceuticals Inc. accounts for 89.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $16,499 and has fallen 91.2% since, to $1,445 in 2025.

$30,312in general payments, 2019–2025

Across 44 payments — averaging $688.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Verity Pharmaceuticals Inc.$27K
  • Procept Biorobotics Corporation$912
  • Boston Scientific$548
  • Ferring Pharmaceuticals Inc.$512
  • Johnson & Johnson$262
  • BD$147
  • plus $884 from 10 others

What the payments were for

  • Consulting fees$11,00036%
  • Speaking & faculty fees$16,00053%
  • Travel & lodging$5452%
  • Food & beverage$2,5098%
  • Education$2581%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,312 in reported general payments places this provider in the 85th percentile of 122 urology providers in Puerto Rico.

See all urology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$80,007
Medicare patients
124
Services billed
544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide39$584,583
TrelstarTriptorelin Pamoate146$372,521
Lupron DepotLeuprolide Acetate24$145,077
MyrbetriqMirabegron111$52,562
Tolterodine Tartrate ErTolterodine Tartrate524$31,141
PremarinEstrogens, Conjugated30$13,323
Tamsulosin Hcl1,219$11,625
Darifenacin ErDarifenacin Hydrobromide96$10,150
Ciprofloxacin Hcl461$4,227
Finasteride306$4,039
Sildenafil Citrate158$3,617
Diclofenac Potassium105$3,350
Oxybutynin Chloride ErOxybutynin Chloride189$3,022
Alfuzosin Hcl ErAlfuzosin Hcl173$2,969
RapafloSilodosin11$2,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$262$584,58339 claims
Verity Pharmaceuticals Inc.Trelstar$27,047$372,521146 claims
AbbVieLupron Depot$68$145,07724 claims
PfizerPremarin$21$13,32330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 122 urology providers in Puerto Rico.

Other urology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →